TG Therapeutics, Inc.

TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases, including autoimmune disorders and hematological malignancies. The company's mission is to develop innovative medicines that deliver novel treatments for patients suffering from these conditions. TG Therapeutics is headquartered in Morrisville, North Carolina, with additional operations in New York.

The company's primary commercial product is BRIUMVI® (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) and other regulatory agencies for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG Therapeutics also maintains a development pipeline that includes a subcutaneous formulation of Ublituximab, Azer-Cel (a CD19 directed allogeneic CAR-T for B-cell disorders), and other investigational medicines such as TG-1701 and TG-1801.

Under the leadership of Chairman, President, and CEO Michael S. Weiss, TG Therapeutics has recently completed enrollment for a Phase 3 trial evaluating a subcutaneous version of BRIUMVI, aiming to expand its market reach. The company has demonstrated strong commercial performance, with BRIUMVI sales driving significant revenue growth, reaching $594 million in 2025 as part of a total revenue of $616 million. Recent financial activities include securing an additional $500 million in non-dilutive capital and expanding its share repurchase program to $300 million.